1号染色体(CFH-CFHR5)或10号染色体(ARMS2/HTRA1)风险等位基因纯合或双纯合个体的年龄相关性黄斑变性进展
这项病例系列研究纳入502例CFH-CFHR5(Chr1)和/或ARMS2/HTRA1(Chr10)风险变异纯合个体,随访至晚期AMD转化和视力下降。校正年龄和基线AMD分级后,Chr1&10-risk组和Chr10-risk组转化为晚期表型的可能性分别约为Chr1-risk组的3.3倍和2.6倍,视力下降2行及以上的可能性分别约为2.1倍和1.8倍。
要点
- Chr1&10-risk组转化为晚期AMD的风险约为Chr1-risk组的3.3倍(95%CI 1.6-6.8;P<.001)。
- Chr10-risk组转化为晚期AMD的风险约为Chr1-risk组的2.6倍(95%CI 1.3-5.2;P=.007)。
- Chr1&10-risk组和Chr10-risk组视力下降2行及以上的风险分别约为Chr1-risk组的2.1倍和1.8倍。
核心结论
- 两个主要AMD相关风险位点与结构和功能疾病进展存在差异关联,并提示这两个位点涉及不同的潜在生物学机制。
- 作者认为这些基因型-表型关联在设计 and 解读AMD研究和临床试验时可能值得考虑。
研究设计与样本
- 这是一项病例系列研究,纳入2009年9月至2020年3月在Sharon Eccles Steele转化医学中心遗传与分子眼病研究 enrolled 的502例个体。
- 纳入对象为Chr1和Chr10风险变异双纯合(Chr1&10-risk)或任一风险变异纯合(Chr1-risk或Chr10-risk)者。
- 研究回顾多模态影像进行AMD分期,包括不完全性和完全性视网膜色素上皮及外层视网膜萎缩分级。
主要发现
- Chr1-risk组317例(首诊中位[IQR]年龄75.6[69.5-81.7]岁;女性193例[60.9%]),Chr10-risk组93例(77.5[72.2-84.2]岁;女性62例[66.7%]),Chr1&10-risk组92例(71.7[68.0-76.3]岁;女性62例[67.4%])。
- 校正首诊年龄和AMD分级后,与Chr1-risk组257例相比,Chr1&10-risk组56例(factor of 3.3[95%CI 1.6-6.8];P<.001)和Chr10-risk组58例(factor of 2.6[95%CI 1.3-5.2];P=.007)随访期间更可能转化为晚期表型。
- 上述差异主要与转化为黄斑新生血管相关,Chr1&10-risk和Chr10-risk组发生更早。
- Chr1&10-risk组(中位[IQR]生存时间5.7[2.1-11.1]年)视力下降2行及以上的可能性是Chr1-risk组(9.4[4.1-*(星号表示事件率未达75%)]年)的2.1倍(95%CI 1.1-3.9;P=.03)。
- Chr10-risk组(中位[IQR]生存时间6.3[2.7-11.3]年)视力下降2行及以上的可能性是Chr1-risk组的1.8倍(95%CI 1.0-3.1;P=.05)。
关键数值与推荐
- 主要结局指标为转化为任何晚期AMD(萎缩型或新生血管型)的风险比和生存时间,以及视力下降2行及以上的风险比和生存时间。
- Chr1&10-risk组转化为晚期AMD的风险比为3.3(95%CI 1.6-6.8;P<.001),Chr10-risk组为2.6(95%CI 1.3-5.2;P=.007),均以Chr1-risk组为参照。
- Chr1&10-risk组视力下降2行及以上的风险比为2.1(95%CI 1.1-3.9;P=.03),Chr10-risk组为1.8(95%CI 1.0-3.1;P=.05),均以Chr1-risk组为参照。
临床怎么用
- 作者认为这些基因型-表型关联在设计 and 解读AMD研究和临床试验时可能值得考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Age-related macular degeneration (AMD) is a common cause of irreversible vision loss among individuals older than 50 years. Although considerable advances have been made in our understanding of AMD genetics, the differential effects of major associated loci on disease manifestation and progression may not be well characterized. OBJECTIVE: To elucidate the specific associations of the 2 most common genetic risk loci for AMD, the CFH-CFHR5 locus on chromosome 1q32 (Chr1) and the ARMS2/HTRA1 locus on chromosome 10q26 (Chr10)-independent of one another and in combination-with time to conversion to late-stage disease and to visual acuity loss. DESIGN, SETTING, AND PARTICIPANTS: This case series study included 502 individuals who were homozygous for risk variants at both Chr1 and Chr10 (termed Chr1&10-risk) or at either Chr1 (Chr1-risk) or Chr10 (Chr10-risk) and who had enrolled in Genetic and Molecular Studies of Eye Diseases at the Sharon Eccles Steele Center for Translational Medicine between September 2009 and March 2020. Multimodal imaging data were reviewed for AMD staging, including grading of incomplete and complete retinal pigment epithelium and outer retinal atrophy. MAIN OUTCOMES AND MEASURES: Hazard ratios and survival times for conversion to any late-stage AMD, atrophic or neovascular, and associated vision loss of 2 or more lines. RESULTS: In total, 317 participants in the Chr1-risk group (median [IQR] age at first visit, 75.6 [69.5-81.7] years; 193 women [60.9%]), 93 participants in the Chr10-risk group (median [IQR] age at first visit, 77.5 [72.2-84.2] years; 62 women [66.7%]), and 92 participants in the Chr1&10-risk group (median [IQR] age at first visit, 71.7 [68.0-76.3] years; 62 women [67.4%]) were included in the analyses. After adjusting for age and AMD grade at first visit, compared with 257 participants in the Chr1-risk group, 56 participants in the Chr1&10-risk group (factor of 3.3 [95% CI, 1.6-6.8]; P < .001) and 58 participants in the Chr10-risk group (factor of 2.6 [95% CI, 1.3-5.2]; P = .007) were more likely to convert to a late-stage phenotype during follow-up. This difference was mostly associated with conversion to macular neovascularization, which occurred earlier in participants with Chr1&10-risk and Chr10-risk. Eyes in the Chr1&10-risk group (median [IQR] survival, 5.7 [2.1-11.1] years) were 2.1 (95% CI, 1.1-3.9; P = .03) times as likely and eyes in the Chr10-risk group (median [IQR] survival, 6.3 [2.7-11.3] years) were 1.8 (95% CI, 1.0-3.1; P = .05) times as likely to experience a visual acuity loss of 2 or more lines compared with eyes of the Chr1-risk group (median [IQR] survival, 9.4 [4.1-* (asterisk indicates event rate did not reach 75%)] years). CONCLUSIONS AND RELEVANCE: These findings suggest differential associations of the 2 major AMD-related risk loci with structural and functional disease progression and suggest distinct underlying biological mechanisms associated with these 2 loci. These genotype-phenotype associations may warrant consideration when designing and interpreting AMD research studies and clinical trials.
引用
- Schmitz-Valckenberg S, Fleckenstein M, Zouache MA, et al. Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both. JAMA Ophthalmol. 2022. PMID: 35113155. doi:10.1001/jamaophthalmol.2021.6072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。